国际医学期刊《美国医学会杂志》刊登了国药集团中国生物发表的《两种新型冠状病毒灭活疫苗对成人COVID-19感染的保护效力评价》。报告总结分析了中国生物所属北京生物制品研究所、武汉生物制品研究所新冠灭活疫苗的有效性、安全性等Ⅲ期临床试验结果。请看本报周五的报道：

Two inactivated vaccines developed by the Chinese pharmaceutical giant Sinopharm have shown to be safe and effective against COVID-19 in phase III human trials, according to a study published in The Journal of the American Medical Association.

The randomized, double-blind and placebo-controlled trials were designed by the Wuhan Institute of Biological Products Co. Ltd., and the Beijing Institute of Biological Products Co. Ltd., both of which belong to the China National Biotec Group (CNBG), affiliated with Sinopharm.

报道中的double-blind就是“双盲的”，即实验者和受试都不知道哪些受试在实验组，哪些在对照组的实验方式。此外还有single-blind (单盲)和open-label (公开标记)的实验方式。